Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 557 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Patient Guide in Colorectal Cancer Now Available in Bulgarian February 18, 2026 FDA Approves Pembrolizumab with Chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical... January 25, 2024 Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... July 30, 2024 Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’ March 4, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Dostarlimab Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in... Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... Gym Offers Free Membership & Support To Those Struggling With Addiction
